Cargando…

Heterogeneous PD-L1 expression in metastases impacts immunotherapy response

Detalles Bibliográficos
Autores principales:	Hu, Xiaoqian, Deng, Xinpei, Xie, Jindong, Tang, Hailin, Zou, Yutian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570695/ https://www.ncbi.nlm.nih.gov/pubmed/37804568 http://dx.doi.org/10.1016/j.ebiom.2023.104816

Ejemplares similares

Is Acupuncture an Ideal Adjunctive Treatment for Cancer-Related Fatigue? Comment on Choi et al. Acupuncture for Managing Cancer-Related Fatigue in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Cancers 2022, 14, 4419
por: Hu, Xiaoqian, et al.
Publicado: (2022)

Recent advances in exosome-based immunotherapy applied to cancer
por: Xie, Jindong, et al.
Publicado: (2023)

The Single‐Cell Landscape of Intratumoral Heterogeneity and The Immunosuppressive Microenvironment in Liver and Brain Metastases of Breast Cancer
por: Zou, Yutian, et al.
Publicado: (2022)

Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A multidimensional analysis
por: Zou, Yutian, et al.
Publicado: (2020)

Advances in artificial intelligence to predict cancer immunotherapy efficacy
por: Xie, Jindong, et al.
Publicado: (2023)

The Role of Circular RNA CDR1as/ciRS-7 in Regulating Tumor Microenvironment: A Pan-Cancer Analysis
por: Zou, Yutian, et al.
Publicado: (2019)

N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer
por: Zou, Yutian, et al.
Publicado: (2022)

Editorial: Tumor microenvironment, immunotherapy, and drug resistance in breast and gastrointestinal cancer
por: Deng, Xinpei, et al.
Publicado: (2023)

Integrative Analysis of KCNK Genes and Establishment of a Specific Prognostic Signature for Breast Cancer
por: Zou, Yutian, et al.
Publicado: (2022)

Multi-omics analyses unravel DNA damage repair-related clusters in breast cancer with experimental validation
por: Liu, Peng, et al.
Publicado: (2023)

Diagnostic and prognostic value of circular RNA CDR1as/ciRS‐7 for solid tumours: A systematic review and meta‐analysis
por: Zou, Yutian, et al.
Publicado: (2020)

Ferroptosis: a new approach for immunotherapy
por: Zeng, Chong, et al.
Publicado: (2020)

Comment on Chen et al. Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin. Biomolecules 2021, 11, 1373
por: Stransky, Nicolai, et al.
Publicado: (2022)

Comment on: Jilkova, Z.M.; et al. “Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
por: Dunnigan, Anna
Publicado: (2020)

Bioengineering of bacteria for cancer immunotherapy
por: Nguyen, Dinh-Huy, et al.
Publicado: (2023)

Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma
por: Herbowski, Leszek
Publicado: (2020)

Cancer immunotherapy comes of age and looks for maturity
por: Finck, Amanda, et al.
Publicado: (2020)

Immunotherapy in COVID-19: why, who, and when?
por: Sinha, Pratik, et al.
Publicado: (2021)

Two contrasting papers stimulate a commentary on the origins of tumour immunology, current cancer immunotherapies, and the future potential for cancer immunotherapy
por: Bodmer, Walter
Publicado: (2022)

2D materials for future heterogeneous electronics
por: Lemme, Max C., et al.
Publicado: (2022)

The Pan-Cancer Multi-Omics Landscape of FOXO Family Relevant to Clinical Outcome and Drug Resistance
por: Xie, Jindong, et al.
Publicado: (2022)

Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer
por: Li, Ming, et al.
Publicado: (2018)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
por: Chatterjee, Samit, et al.
Publicado: (2017)

Acquired mechanisms of immune escape in cancer following immunotherapy
por: Bryan Iorgulescu, J., et al.
Publicado: (2018)

Immunotherapies for COVID-19: lessons learned from sepsis
por: Remy, Kenneth E, et al.
Publicado: (2020)

From macrophage biology to macrophage-based cellular immunotherapies
por: Mass, Elvira, et al.
Publicado: (2021)

Immune-related adverse events and the balancing act of immunotherapy
por: Conroy, Michael, et al.
Publicado: (2022)

Potential solutions for manufacture of CAR T cells in cancer immunotherapy
por: Blache, Ulrich, et al.
Publicado: (2022)

Towards evidence-based response criteria for cancer immunotherapy
por: Garralda, Elena, et al.
Publicado: (2023)

Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
por: O’Donnell, Jake S., et al.
Publicado: (2016)

PD-L1 expression in breast cancer brain metastases
por: Chehade, Rania, et al.
Publicado: (2022)

COVID-19 vaccination and cancer immunotherapy: should they stick together?
por: Brest, Patrick, et al.
Publicado: (2021)

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
por: Abid, Muhammad Bilal
Publicado: (2022)

T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all
por: Gaudeaux, P., et al.
Publicado: (2022)

Heterogeneity in clinical sequencing tests marketed for autism spectrum disorders
por: Hoang, Ny, et al.
Publicado: (2018)

Managing COVID-19 importation risks in a heterogeneous world
por: Cauchemez, Simon, et al.
Publicado: (2021)

T-cell tumour exclusion and immunotherapy resistance: a role for CAF targeting
por: Hanley, Christopher J., et al.
Publicado: (2020)

Heterogeneity and cell fate flux in single human pancreatic islet cells
por: Ng, Natasha H. J., et al.
Publicado: (2018)

Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer
por: Chakraborty, Goutam, et al.
Publicado: (2023)

T follicular helper and B cell crosstalk in tertiary lymphoid structures and cancer immunotherapy
por: Garaud, Soizic, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4knk111f5o3pue39306nnooc63